November 11, 2026 · Climacteric : the journal of the International Menopause Society · DOI: 10.1080/13697137.2026.2751395

A new concept for 'starting menopause hormone therapy' using an oral GnRH antagonist with an estrogen and a progestin (or an estrogen and a selective estrogen receptor modulator): why must we wait to treat women in perimenopause?

Listen to this summary

This proof-of-concept paper proposes a "starting menopause hormone therapy" (sMHT) approach that uses an oral GnRH antagonist combined with an estrogen and a progestin (or a SERM) to treat vasomotor symptoms and abnormal uterine bleeding as soon as they appear in perimenopause, rather than waiting for 12 months of amenorrhea. The authors ask whether the availability of oral GnRH antagonists makes it possible to start hormone treatment earlier in symptomatic perimenopausal women, avoiding the safety and adherence drawbacks of combined oral contraceptives or sequential estro-progestin regimens. They suggest that sMHT could later transition to conventional MHT once ovarian function has definitively ceased.

Giovanni Grandi, Marta Barretta, Antonio La Marca, Massimo Stomati, Alessandro Gambera, Fabio Facchinetti, Agnaldo Lopes da Silva Filho, Rossella Elena Nappi

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play